| Ident. | Authors (with country if any) | Title |
|---|
| 000828 |
T. Slaoui [France] ; A. Mas-Gerdelat [France] ; F. Ory-Magne [France] ; O. Rascol [France] ; C. Brefel-Courbon [France] | La lévodopa modifie les seuils nociceptifs chez le patient parkinsonien |
| 000A97 |
Carl E. Clarke [Royaume-Uni] ; O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. Melamed [Israël] ; W. Oertel [Allemagne] ; Werner Poewe [Autriche] ; F. Stocchi [Italie] ; E. Tolosa [Espagne] | Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study) : a randomised, double-blind, parallel-group trial. Commentary |
| 000E32 |
J. L. Montastruc [France] ; O. Rascol [France] | Propriétés pharmacodynamiques des agonistes dopaminergiques ? Quelle transférabilité en pratique clinique dans le traitement de la maladie de Parkinson ? |
| 000E33 |
O. Rascol [France] ; J.-J. Ferreira [Portugal] ; P. Payoux [France] ; Ch. Brefel-Courbon [France] ; J.-L. Montastruc [France] | Prise en charge des dyskinésies par la lévodopa |
| 000E77 |
M. Simonetta Moreau [France] ; S. Meunier [France] ; M. Vidailhet [France] ; S. Pol [France] ; M. Galitzky [France] ; O. Rascol [France] | Transmission of group II heteronymous pathways is enhanced in rigid lower limb of de novo patients with Parkinson's disease |
| 001001 |
O. Rascol [France] ; J. Ferreira [France, Portugal] ; J.-L. Montastruc [France] | Pharmacologie: Somnolence diurne anormale, « attaques de sommeil » et médicaments antiparkinsoniens |
| 001060 |
O. Rascol [France] ; J. G. Nutt [États-Unis] ; O. Blin [France] ; C. G. Goetz [États-Unis] ; J. M. Trugman [États-Unis] ; C. Soubrouillard [France] ; J. H. Carter [États-Unis] ; L. J. Currie [États-Unis] ; N. Fabre [France] ; C. Thalamas [France] ; W. J. Giardina [États-Unis] ; S. Wright [États-Unis] | Induction by Dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with parkinson Disease |
| 001064 |
O. Rascol [France] ; I. Arnulf [France] ; H. Peyro-Saint Paul [France] ; C. Brefel-Courbon [France] ; M. Vidailhet [France] ; C. Thalamas [France] ; A. M. Bonnet [France] ; S. Descombes [France] ; B. Bejjani [France] ; N. Fabre [France] ; J. L. Montastruc [France] ; Yves Agid [France] | Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease |
| 001143 |
O. Rascol [France] ; J.-L. Montastruc [France] | La place des agonistes dopaminergiques |
| 001176 |
O. Rascol [France] | The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease |
| 001196 |
O. Rascol [France] | Medical treatment of levodopa-induced dyskinesias |
| 001248 |
O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; A. D. Korczyn [Israël] ; P. P. De Deyn [Belgique] ; C. E. Clarke [Royaume-Uni] ; A. E. Lang [Canada] | A five-year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa |
| 001264 |
C. Brefel-Courbon ; O. Rascol | Scintigraphies cérébrales et syndromes parkinsoniens |
| 001283 |
O. Rascol [France] | Arguments en faveur du traitement précoce de la maladie de Parkinson par les agonistes dopaminergiques |
| 001290 |
J. L. Montastruc [France] ; O. Rascol [France] ; J.-M. Senard [France] | Treatment of Parkinson's disease should begin with a dopamine agonist |
| 001329 |
C. Thalamas [France] ; A. Taylor [Royaume-Uni] ; C. Brefel-Courbon [France] ; S. Eagle [Royaume-Uni] ; K. Fitzpatrick [Royaume-Uni] ; O. Rascol [France] | Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease |
| 001330 |
O. Rascol [France] | L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease : A clinical pharmacologic approach |
| 001369 |
O. Rascol [France] ; O. Blin [France] ; C. Thalamas [France] ; S. Descombes [France] ; C. Soubrouillard [France] ; P. Azulay [France] ; N. Fabre [France] ; F. Viallet [France] ; K. Lafnitzegger [États-Unis] ; S. Wright [États-Unis] ; J. H. Carter [États-Unis] ; J. G. Nutt [États-Unis] | ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's Disease |
| 001371 |
H. Bagheri [France] ; C. Damase-Michel [France] ; M. Lapeyre-Mestre [France] ; S. Cismondo [France] ; D. O'Connell [Irlande (pays)] ; J.-M. Senard [France] ; O. Rascol [France] ; J.-L. Montastruc [France] | A study of salivary secretion in Parkinson's disease |
| 001373 |
J.-L. Montastruc [France] ; M. Ziegler [France] ; O. Rascol [France] ; M. Malbezin [France] | A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease |
| 001416 |
A. E. Schrag [Royaume-Uni] ; D. J. Brooks [Royaume-Uni] ; E. Brunt [Pays-Bas] ; D. Fuell [Royaume-Uni] ; A. Korczyn [Israël] ; Werner Poewe [Autriche] ; N. P. Quinn [Royaume-Uni] ; O. Rascol [France] ; F. Stocchi [Italie] | The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease |
| 001421 |
A. D. Korczyn [Israël] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; Werner Poewe [Autriche] ; O. Rascol [France] ; F. Stocchi [Italie] | Ropinirole versus bromocriptine in the treatment of early Parkinson's disease : A 6-month interim report of a 3-year study |
| 001422 |
O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; A. D. Korczyn [Israël] ; Werner Poewe [Autriche] ; F. Stocchi [Italie] | Ropinirole in the treatment of early Parkinson's disease : A 6-month interim report of a 5-year levodopa-controlled study |
| 001448 |
J. L. Montastruc [France] ; M. Pelat [France] ; P. Verwaerde [France] ; C. Brefel-Courbon [France] ; M. A. Tran [France] ; O. Blin [France] ; O. Rascol [France] ; J. M. Senard [France] | Fluoxetine in orthostatic hypotension of Parkinson's disease : A clinical and experimental pilot study |
| 001454 |
C. Brefel [France] ; C. Thalamas [France] ; S. Rayet [France] ; A. Lopez-Gil [Royaume-Uni] ; K. Fitzpatrick [Royaume-Uni] ; S. Bullman [Royaume-Uni] ; D. R. Citerone [Royaume-Uni] ; A. C. Taylor [Royaume-Uni] ; J. L. Montastruc [France] ; O. Rascol [France] | Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients |
| 001469 |
D. J. Brooks [Royaume-Uni] ; R. J. Abbott [Royaume-Uni] ; A. J. Lees [Royaume-Uni] ; E. Martignoni [Italie] ; D. V. Philcox [Afrique du Sud] ; O. Rascol [France] ; R. A. C. Roos [Pays-Bas] ; H. J. Sagar [Royaume-Uni] | A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease |
| 001497 |
J.-L. Montastruc [France] ; O. Rascol [France] ; J.-M. Senard [France] | Pharmacologie des médicaments antiparkinsoniens : bilan et perspectives : Maladie de Parkinson |
| 001498 |
N. Fabre [France] ; C. Brefel-Courbon [France] ; O. Rascol [France] | Parkinson « plus » : Mouvements anormaux |
| 001519 |
O. Rascol [France] ; N. Fabre [France] ; U. Sabatini [Italie] | Imagerie fonctionnelle |
| 001523 |
O. Rascol [France] ; N. Fabre [France] ; J.-L. Montastruc [France] | Fluctuations de la réponse à la L-dopa dans la maladie de Parkinson : Maladie de Parkinson - 2e partie |
| 001535 |
C. Soubrouillard [France] ; C. Lombardo [France] ; O. Rascol [France] ; B. Bruguerolle [France] ; O. Blin [France] | Agonistes dopaminergiques centraux D1 et traitement de la maladie de Parkinson |
| 001546 |
O. Rascol [France] ; U. Sabatini [Italie] ; N. Fabre [France] ; C. Brefel [France] ; I. Loubinoux [France] ; P. Celsis [France] ; J. M. Senard [France] ; J. L. Montastruc [France] ; F. Chollet [France] | The ipsilateral cerebellar hemisphere is overactive during hand movements in akinetic parkinsonian patients |
| 001600 |
N. Andreu [France] ; C. Damase-Michel [France] ; J.-M. Senard [France] ; O. Rascol [France] ; J.-L. Montastruc [France] | A dose-ranging study of selegiline in patients with Parkinson's disease : Effect on platelet monoamine oxidase activity |
| 001636 |
O. Rascol [France] ; A. J. Lees ; J. M. Senard [France] ; Z. Pirtosek ; J. L. Montastruc [France] ; D. Fuell | Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease |
| 001672 |
M.-E. Llau [France] ; G. Durrieu [France] ; M.-A. Tran [France] ; J.-M. Senard [France] ; O. Rascol [France] ; J.-L. Montastruc [France] | A study of dopaminergic sensitivity in Parkinson's disease : Comparison in ''de novo'' and levodopa-treated patients |
| 001733 |
J.-L. Montastruc [France] ; N. Fabre [France] ; O. Blin [France] ; J.-M. Senard [France] ; O. Rascol [France] ; A. Rascol [France] | Does fluoxetine aggravate Parkinson's disease ? A pilot prospective study |
| 001743 |
O. Rascol [France] ; U. Sabatini ; N. Fabre [France] ; J. M. Senard [France] ; M. Simonetta-Moreau [France] ; J. L. Montrastruc [France] ; M. Clanet [France] ; A. Rascol [France] | Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease |
| 001791 |
O. Rascol [France] ; U. Sabatini [France] ; F. Chollet [France] ; N. Fabre [France] ; J. M. Senard [France] ; J. L. Montastruc [France] ; P. Calsis [France] ; J. P. Marc-Vergnes [France] ; A. Rascol [France] | Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa |
| 001792 |
O. Rascol [France] ; N. Fabre [France] ; O. Blin ; J. Poulik [France] ; U. Sabatini [France] ; J.-M. Senard [France] ; M. Ane [France] ; J.-L. Montastruc [France] ; A. Rascol | Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease |
| 001795 |
O. Blin [France] ; C. Desnuelle ; O. Rascol ; M. Borg ; H. Peyro Saint Paul ; J. P. Azulay [France] ; F. Bille [France] ; D. Figarella [France] ; F. Coulom [France] ; J. F. Pellissier [France] ; J. L. Montastruc ; M. Chatel ; G. Serratrice [France] | Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy |
| 001798 |
H. Bagheri [France] ; M. Berlan ; J. M. Senard ; O. Rascol ; J. L. Montastruc | Lacrimation in Parkinson's disease |
| 001804 |
J. L. Montastruc [France] ; M. E. Llau ; O. Rascol ; J. M. Senard | Drug-induced parkinsonism : a review |
| 001815 |
J.-F. Demonet [France] ; P. Celsis [France] ; A. Agniel [France] ; D. Cardebat [France] ; O. Rascol [France] ; J.-P. Marc-Vegnes [France] | Activation of regional cerebral blood flow by a memorization task in early Parkinson's disease patients and normal subjects |
| 001816 |
J. L. Montastruc [France] ; O. Rascol [France] ; J. M. Senard [France] ; A. Rascol | A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease : a five year follow up |
| 001846 |
J. M. Senard [France] ; O. Rascol [France] ; B. Chamontin [France] ; A. Rascol [France] ; J.-L. Montastruc [France] | Enregistrement ambulatoire de la pression artérielle dans l'hypotension orthostatique de la maladie de Parkinson |
| 001874 |
J. M. Senard [France] ; O. Rascol [France] ; A. Rascol ; J. L. Montastruc [France] | Lack of yohimbine effect on ambulatory blood pressure recording : a double-blind cross-over trial in Parkinsonians with orthostatic hypotension |
| 001885 |
J. M. Senard [France] ; O. Rascol [France] ; G. Durrieu [France] ; M. A. Tran [France] ; M. Berlan [France] ; A. Rascol ; J. L. Montastruc | Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy |
| 001893 |
J. L. Montastruc [France] ; O. Rascol ; J. M. Senard | Current status of dopamine agonists in Parkinson's disease management |
| 001900 |
N. Fabre [France] ; J. L. Montastruc ; O. Rascol | Alopecia : an adverse effect of bromocriptine |
| 001954 |
A. Kastner [France] ; E. C. Hirsch ; O. Lejeune ; F. Javoy-Agid ; O. Rascol [France] ; Yves Agid [France] | Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content ? |
| 001998 |
J. L. Montrastuc [France] ; O. Rascol ; J. M. Senard ; V. Gualano ; H. Bagheri ; G. Houin ; A. Lees ; A. Rascol | Sublingual apomorphine in Parkinson's disease : a clinical and pharmacokinetic study |
| 001999 |
U. Sabatini [France] ; O. Rascol ; P. Celsis ; G. Houin ; A. Rascol ; J. P. Marc-Vergnes ; J. L. Montastruc | Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms |
| 001A00 |
O. Rascol [France] ; U. Sabatini ; SIMONETTA-MOREAU ; J. L. Montastruc ; A. Rascol ; M. Clanet | Square wave jerks in Parkinsonian syndromes |
| 001A33 |
J.-L. Montastruc [France] ; O. Rascol ; J.-M. Senard | Les médicaments anti-parkinsoniens : bilan et nouvelles perpectives pharmacologiques |
| 001A43 |
J. L. Montastruc ; O. Rascol ; A. Rascol | Comparison de la bromocriptine et de la levodopa dans le traitement de première intention de la maladie de Parkinson : résultats à 3 ans d'une étude prospective randomisée |
| 001A53 |
U. Sabatini ; O. Rascol ; A. Rascol ; J.-L. Montastruc | Migraine attacks induced by subcutaneous apomorphine in two migrainous parkinsonian patients |
| 001A62 |
O. Rascol ; N. Fabre ; H. Teraêvaêinen ; Werner Poewe [Autriche] ; C. Luêcking ; U. Rinne ; E. Dupont ; D. Hirt ; M. Hoyer ; X. Lataste | CQA 206-291 : a novel dopamine agonist in the treatment of Parkinson's disease |
| 001A91 |
M. Berlan ; O. Rascol ; J. Belin ; J.-P. Moatti ; A. Rascol ; J.-L. Montastruc | α2-Adrenergic sensitivity in Parkinson's disease |
| 001B01 |
O. Rascol ; M. Clanet ; J. L. Montastruc ; M. Simonetta ; M. J. Soulier-Esteve ; B. Doyon ; A. Rascol | Abnormal ocular movements in Parkinson's disease: evidence for involvement of dopaminergic systems |
| 001B17 |
J.-P. Marc-Vergnes ; P. Celsis ; J. L. Montastruc ; J. F. Demonet ; A. Agniel ; O. Rascol ; G. Viallard ; B. Doyon ; A. Rascol | Hémodynamique cérébrale et pharmacologie clinique dans la maladie de Parkinson |
| 001B18 |
P. Celsis ; O. Rascol ; J. F. Demonet ; A. Agniel ; J. L. Montastruc ; J. P. Marc-Vergnes ; A. Rascol | Effet de la bromocriptine sur le débit sanguin cérébral dans la maladies de Parkinson |
| 001B20 |
J. L. Montastruc ; O. Rascol ; A. Rascol | Bromocriptine versus levodopa dans le traitement de première intention de la maladie de Parkinson. Premiers résultats à deux ans |
| 001B21 |
O. Rascol ; J. L. Montastruc ; J. M. Senard ; J. F. Demonet ; M. Simonetta ; A. Rascol | Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trial |
| 001B63 |
J. L. Montastruc ; O. Rascol ; J. Belin ; M. Ane ; A. Rascol | Does papaverine interact with levodopa in Parkinson's disease? |
| 001B78 |
A. Rascol ; J. L. Montastruc ; O. Rascol ; J. M. Senard | Mesulergine (CU 32-085) in the treatment of Parkinson's disease |
